# US 9,872,895 B2 · TLR5 ligands, therapeutic methods, and compositions related thereto > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,872,895 B2 - Document ID: US9872895B2 - Status: Granted - Kind: B2 - Application number: 13/825,349 - Filed: 2011-09-20 - Published: 2015-06-18 - Granted: 2018-01-23 - Earliest claimed: 2010-09-24 - Assignees: Emory University - Applicants: Andrew T. Gewirtz; Benyue Zhang - Inventors: Andrew T. Gewirtz; Benyue Zhang - Web page: https://patentgrep.com/patent/US9872895B2 ## CPC - A61K 39/02: Bacterial antigens - A61K 38/164: {from bacteria} - A61K 38/21: Interferons {[IFN]} - A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/12: Antivirals - A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation} - C12N 2720/12371: Demonstrated in vivo effect - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The disclosure relates to antiviral therapeutic methods and related compositions. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection by administering a pharmaceutical composition comprising a TLR5 ligand, such as a flagellin, to a subject in need thereof. ## Claims ### Claim 1 A method of treating a viral infection comprising administering an isolated flagellin in an effective amount to activate TLR5 to subject that is diagnosed with, suspected of, or exhibiting symptoms of a viral infection wherein the isolated flagellin is administered in the absence of administering a viral vaccine comprising viral nucleic acid or viral antigen. ### Claim 2 (depends on 1) The method of claim 1, wherein the isolated flagellin comprises SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12. ### Claim 3 (depends on 1) The method of claim 1, wherein the subject is a human. ### Claim 4 (depends on 1) The method of claim 1, wherein isolated flagellin is administered in combination with a second antiviral agent. ### Claim 5 (depends on 1) The method of claim 1, wherein isolated flagellin is administered in combination with abacavir, acyclovir, adefovir, amantadine, amprenavir, rintatolimod, umifenovir, atazanavir, boceprevir, cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, interferon type III, interferon type II, interferon type I, lamivudine, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, oseltamivir, peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin, raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, stavudine, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, tromantadine, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine zalcitabine, zanamivir, and/or zidovudine. ### Claim 6 (depends on 1) The method of claim 1, wherein the subject has a compromised immune system. ### Claim 7 (depends on 1) The method of claim 1, wherein the subject is an organ transplant recipient, undergoing hemodialysis, diagnosed with cancer, receiving an immunosuppressive drug, or diagnosed with an HIV-infection. ### Claim 8 A pharmaceutical composition comprising an isolated flagellin and a second antiviral agent wherein the second antiviral agent is selected from abacavir, acyclovir, adefovir, amantadine, amprenavir, rintatolimod, umifenovir, atazanavir, boceprevir, cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, interferon type III, interferon type II, interferon type I, lamivudine, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, oseltamivir, peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin, raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, stavudine, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, tromantadine, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine zalcitabine, zanamivir, and zidovudine. ### Claim 9 A pharmaceutical composition comprising an isolated flagellin and efavirenz, emtricitabine, and tenofovir disoproxil. ### Claim 10 A pharmaceutical composition comprising an isolated flagellin and abacavir, lamivudine, and zidovudine. ### Claim 11 A pharmaceutical composition comprising an isolated flagellin and emtricitabine and tenofovir disoproxil. ### Claim 12 (depends on 1) The method of claim 1, wherein the isolated flagellin is administered in combination with efavirenz, emtricitabine and tenofovir disoproxil. ### Claim 13 (depends on 1) The method of claim 1, wherein the isolated flagellin is administered in combination with abacavir, lamivudine, and zidovudine. ### Claim 14 (depends on 1) The method of claim 1, wherein isolated flagellin is administered in combination with emtricitabine and tenofovir disoproxil. ### Claim 15 (depends on 1) The method of claim 1, wherein the subject is diagnosed with a rotaviral infection. ### Claim 16 (depends on 1) The method of claim 1, wherein the subject is diagnosed with an influenza viral infection.